Inbrija is a drug owned by Merz Pharmaceuticals Llc A Sub Of Merz Therapeutics Gmbh. It is protected by 18 US drug patents filed in 2019. Out of these, 5 drug patents are active and 13 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 16, 2032. Details of Inbrija's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Inbrija's patents.

Latest Legal Activities on Inbrija's Patents

Given below is the list of recent legal activities going on the following patents of Inbrija.

Activity	Date	Patent Number
Critical Events This Week
Payment of Maintenance Fee, 8th Year, Large Entity	03 Jan, 2024	US9393210
Expire Patent Critical	20 Nov, 2023	US9155699
Maintenance Fee Reminder Mailed Critical	05 Jun, 2023	US9155699
Expire Patent Critical	21 Feb, 2022	US8628754
Maintenance Fee Reminder Mailed Critical	06 Sep, 2021	US8628754
Payment of Maintenance Fee, 8th Year, Large Entity	05 May, 2021	US8586093
Payment of Maintenance Fee, 8th Yr, Small Entity	17 Mar, 2021	US8545878
Payment of Maintenance Fee, 12th Year, Large Entity	23 Dec, 2020	US7556798
Payment of Maintenance Fee, 8th Year, Large Entity	10 Sep, 2020	US8404276
Payment of Maintenance Fee, 4th Year, Large Entity	09 Jan, 2020	US9393210

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Inbrija and ongoing litigations to help you estimate the early arrival of Inbrija generic.

Inbrija's Litigations

Inbrija been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 27, 2004, against patent number US7556798. The petitioner , challenged the validity of this patent, with David A. Edwards et al as the respondent. Click below to track the latest information on how companies are challenging Inbrija's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US7556798	May, 2007	Decision (18 Aug, 2008)	David A. Edwards et al
US7556798	August, 2004	Decision (18 Mar, 2005)	David A. Edwards et al

FDA has granted some exclusivities to Inbrija. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Inbrija, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Inbrija.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

US patents provide insights into the exclusivity only within the United States, but Inbrija is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Inbrija's family patents as well as insights into ongoing legal events on those patents.

Inbrija's Family Patents

Inbrija has patent protection in a total of 22 countries. It's US patent count contributes only to 24.1% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Inbrija.

Full family tree

Generic Launch

About Inbrija

Inbrija is a drug owned by Merz Pharmaceuticals Llc A Sub Of Merz Therapeutics Gmbh. It is used for managing off episodes in Parkinson's disease patients treated with carbidopa/levodopa through the inhalation of levodopa powder particles. Inbrija uses Levodopa as an active ingredient. Inbrija was launched by Merz Pharms in 2018.